2024 Potthoff k et al.: ann oncol. 2010

Potthoff k et al.: ann oncol. 2010

Author: oqkf

August undefined, 2024

Web25 Aug 2024 · Ann Oncol 26:i60, 2015 (suppl 1; abstr LBA3) Google Scholar: 10. Ballard P, Yates JW, Yang Z, et al: Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 22: 5130-5140, 2016 Crossref, Medline, Google Scholar: 11. Web19 Dec 2024 · Kang YK, Boku N, Satoh T. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous …

Interdisciplinary management of EGFR-inhibitor-induced skin ... - PubMed

WebTable 28: Management of papulopustular rash associated with multikinase inhibitors by CTCAE grade1, 4-10. Grade. Description. 1. May be treated with hydrocortisone cream (1% … Web2 Sep 2024 · In the absence of studies comparing the different ADT combination regimens (abiraterone, enzalutamide, apalutamide, and docetaxel), several factors may be … dr ousmane ka

Ionisierende Strahlen Gesundheitliche Folgen des Unfalls von ...

Web1 Mar 2011 · BACKGROUND Anti-epidermal growth factor receptor treatment strategies, i.e. monoclonal antibodies such as cetuximab and panitumumab, or epidermal growth factor … Web4 Jul 2024 · Ann Oncol. 2024; 29 (abstr).: 872P. ... Semin Liver Dis. 2010; 30: 52-60. View in Article Scopus (2886) PubMed; Crossref; Google Scholar; 23. Kudo M ... Dykema K ; et al. Overexpression of HGF promotes HBV-induced hepatocellular carcinoma progression and is an effective indicator for Met-targeting therapy. Web22 Nov 2009 · INTRODUCTION. Lung cancer is the leading cause of cancer death worldwide for both men and women ().Among patients who underwent surgery for this condition, 36.5% were diagnosed as clinical stage IA ().Lobectomy with lymph node dissection remains a standard initial therapy even in clinical stage IA non-small cell lung cancer (NSCLC) ().The … ras-50njp/rac-50np

Phase III Randomized Trial of Lobectomy Versus Limited …

Osimertinib As First-Line Treatment of EGFR Mutation–Positive …

WebThe relationship between habit and healthcare professional behaviour in clinical practice: a systematic review and meta-analysis Sebastian Potthoﬀ a,b, Othman Rasulb, Falko F. Sniehotta c, Marta Marquesd, Fiona Beyer b, Richard Thomsonb, Leah Avery e and Justin Presseau f,g,h aFaculty of Health and Life Sciences, Northumbria University, Newcastle … Web10 Apr 2024 · Immunotherapy with monoclonal antibodies (MoAbs) targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and the programmed death-1 receptor (PD-1) and its ligand PD-L1 has become standard of care for an increasing number of indications (Table 1). Therefore, an increasing number of patients will be exposed to these drugs with a … dr ovakimyanWeb15 Dec 2024 · For patients with peripheral T-cell lymphoma (PTCL), outcomes using frontline treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy are typically poor. The ECHELON-2 study demonstrated that brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP) … ras-50njp/rac-50jp

"Webmultiple actors” (Pentland et al., 2010 p. 95). For example, the manage-ment of acute stroke care patients in the emergency department involves multiple HCPs working together in a … " - Potthoff k et al.: ann oncol. 2010

Potthoff k et al.: ann oncol. 2010

Webselect article Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2024, Pages 1015-1024] WebThe use of cytotoxic chemotherapy is associated with a response rate of 20 to 35% and a median survival time of 10 to 12 months among patients with advanced non–small-cell …

Did you know?

WebBackground: In the phase III KEYNOTE-061 trial (NCT02370498), pembrolizumab did not significantly improve overall survival versus paclitaxel as second-line therapy for … Web24 Jun 2024 · A multi-cancer early detection (MCED) test used to complement existing screening could increase the number of cancers detected through population screening, …

Web31 May 2014 · Background: Oncoplastic surgery (OPS) has emerged as a new approach for extending breast conserving surgery (BCS) possibilities, reducing both mastectomy and re … Web21 Oct 2024 · Ann Surg Oncol. 2010; 17: 1471-1474. View in Article Scopus (6282) PubMed; Crossref; Google Scholar; 16. Eisenhauer EA ; Therasse P ; Bogaerts J ; et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). ... Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with ...

WebLokal ablative Verfahren sind seit über 20 Jahren integraler Bestandteil der Therapie onkologischer Erkrankungen. Wurden früher überwiegend chemische Verfahren eingesetzt (z. B. perkutane Ethanolinstillation, PEI), werden heute v.a. thermische … Web10 Sep 2013 · J Cancer Res Clin Oncol. 2010; 136: 737-743. Crossref; PubMed; ... Ann Oncol. 2012; 23: 1531-1536. ... Naeim A, Lin L, Dichmann R, et al. Phase II study of front-line capecitabine (CAP) and bevacizumab (BEV) in frail and elderly patients with metastatic colorectal cancer (mCRC). American Society of Clinical Oncology Gastrointestinal …

WebDosage adjustments are often necessary in HD cancer patients. These adaptations have to be carefully carried out to optimize drug exposure, ensure efficacy and reduce the risk of …

Web19 Dec 2024 · Ann Oncol 2009; 20 (9): 1529–1534. ... Lancet 2010; 376 (9742): 687–697. [Google Scholar] ... Wilke H, Muro K, Van Cutsem E. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma ... dr ousmane kabaWebDescription. 1. Antimicrobial soaks: 1:1 vinegar in warm water, diluted bleach (0.005%), povidone iodine 1:10, potassium permanganate 1:10,000, 2-3 times a day 15-20 minutes … ras-50njk+rac-50nk1Web1 Gastroenterology / Endosonography, Johannes-Gutenberg University Clinic, 55131 - Mainz/DE; 2 Gastroenterology And Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP; 3 Hemato-oncology, Clinica San Carlos de Apoquindo, Pontificia Universidad Católica, 7550000 - Santiago RM/CL; 4 Medical Oncology, … dr ouzzaniWebAbstract. Background: Screening tools are proposed to identify those older cancer patients in need of geriatric assessment (GA) and multidisciplinary approach. We aimed to update … ras-50uk/rac-50ukWebet al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, multicenter trial comparing single daily moxofloxacin with twice daily ciprofloxacin plus … dr ovadje stockbridgeWeb5 Nov 2024 · Skubitz K ; et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010; 11: 275-280. Summary; Full Text; ... Ann Surg Oncol. 2010; 17: 694-701. View in Article Scopus (47) PubMed; Crossref; Google Scholar; 22. Mondal A ; Kundu B ; Gupta S ; Biswas J ; Secondary malignant giant cell tumour of ... dr ovaiciWebexperimental trial literature (Potthoff, Rasul, et al., submitted). A better understanding of how and under what conditions habit influences HCP behaviour could help to design more … ras-63njk/rac-63jk